Roche to launch new CGM in Europe

Roche is set to launch its Accu-Chek Smartguide in the Netherlands, Switzerland, and Germany, aiming to differentiate itself with hypoglycemia prediction features. The device, approved in July with a CE mark for individuals 18 and older with Type 1 or Type 2 diabetes, can be worn for 14 days.

Accu-Chek Smartguide’s predictive algorithms set it apart from competitors like Abbott and Dexcom, though it initially requires fingerstick calibration, unlike newer CGMs. Roche’s device offers three predictive tools: forecasting low glucose within 30 minutes, predicting levels over the next two hours, and assessing nighttime hypoglycemia risk.

Using machine learning, these predictions are based on patient data, offering a broader view than standard CGM trend arrows. Roche’s trials showed the device accurately predicted low glucose levels within 30 minutes with 95% sensitivity and 99% specificity.

Roche plans to enhance the device with new features, including MySugr app integration and improved sensors.